2016 Press Releases Communiqués de presse

December 22, 2016 22 December, 2016

Sernova to Present Corporate and JDRF-Sponsored Clinical Trial Update at the Biotech Showcase™ 2017 Healthcare Conference in San Francisco

November 2, 2016 2 November, 2016

Sernova and CTI Clinical Trial Announce Regulatory Collaboration

September 30, 2016 30 September, 2016

Sernova Announces Appointment of New CFO

July 12, 2016 12 July, 2016

Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patie

June 30, 2016 30 June, 2016

SERNOVA COMPLETES PRIVATE PLACEMENT OF $4,200,000

June 29, 2016 29 June, 2016

Sernova Increases Private Placement to $4,200,000

June 27, 2016 27 June, 2016

Sernova Announces $2,000,000 First Closing of Private Placement

June 21, 2016 21 June, 2016

Sernova Announces Non-brokered Private Placement

March 15, 2016 15 March, 2016

Sernova Announces First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update

February 16, 2016 16 February, 2016

Sernova Receives First Payment from the European Commission’s Horizon 2020 Grant to Fund Development of a Cell-Based Hemophilia Therapeutic Using th

February 5, 2016 5 February, 2016

Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies

January 26, 2016 26 January, 2016

Sernova Announces Agreement with CCRM to Produce Specialized Cells for the Treatment of Diabetes

January 6, 2016 6 January, 2016

Sernova Corp to Present at the Biotech Showcase™ 2016 in San Francisco on January 13, 2016

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 22, 2016 22 December, 2016

Sernova to Present Corporate and JDRF-Sponsored Clinical Trial Update at the Biotech Showcase™ 2017 Healthcare Conference in San Francisco


Source: Sernova Corp December 22, 2016, 6:00 a.m. EDT

LONDON, Ontario, December 22, 2016– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, is pleased to announce that Dr. Philip Toleikis, Sernova’s President and CEO, will present an update on the company’s corporate and business strategy at the 9th annual Biotech Showcase Conference in San Francisco, CA. This important conference brings together global industry leaders, emerging companies and key members of the pharmaceutical and investment community.

“We are presenting Sernova’s corporate and strategic regenerative medicine approach including details of our upcoming JDRF-sponsored Phase I/II clinical trial for patients with type 1 diabetes as well as product development advancements during the industry’s largest conglomerate of annual healthcare conferences and arguably the most important healthcare investment symposia in the industry,” remarked Dr. Philip Toleikis, President and CEO.

“With Sernova anticipating upcoming release of information pertaining to its industry partnerships, and collaborations, this is an excellent opportunity to highlight the company’s progress and future direction,” added Dr. Toleikis. The presentation will occur January 10, 2017 at 2:00 p.m. at the Hilton San Francisco, Union Square, 333 O’Farrell St, Ballroom Level, Room 7. About Biotech Showcase(TM)

Biotech Showcase(TM) is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential partners in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year. Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives Now in its ninth year, Biotech Showcase is expected to attract upwards of 2,000 attendees. The meeting is being held January 9-11, 2017 in San Francisco, CA at the Hilton, San Francisco, Union Square.

About Sernova

Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - November 02, 2016 2 November, 2016

Sernova and CTI Clinical Trial Announce Regulatory Collaboration


Sernova provides update on its plans for IND filing with US FDA

LONDON, ONTARIO – (Marketwire – November 2, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia and CTI Clinical Trial and Consulting Services (CTI), are pleased to announce their collaboration on regulatory matters respecting Sernova’s Cell Pouch System(TM), a novel implantable and scalable medical device that when combined with therapeutic cells, may provide a convenient, safe and effective long-term therapeutic option for patients with chronic diseases such as insulin-dependent diabetes who seek to improve their quality of life.

CTI as an expert in cell therapy, and immunology among other life-changing therapies in critically and chronically ill patients is supporting Sernova’s clinical trial regulatory processes including submission of Sernova’s regulatory package with the FDA for the recently announced JDRF supported clinical trial in patients with insulin-dependent diabetes. In this regard CTI has been a part of more than 100 drug and device approvals and has proven success in advancing numerous international drug and device applications.

“We are really enthused to be collaborating with Sernova on filing their Investigational New Drug (IND) application with the US FDA,” stated Timothy Schroeder, CTI Founder and CEO. “Sernova is an innovative organization with a regenerative medicine program that could change the standard of care for many chronically ill patients.”

“We are pleased to have CTI supporting Sernova’s clinical trial regulatory processes as they bring proven expertise in medical device and regenerative medicine technologies targeting chronically ill patient populations,” remarked Dr. Philip Toleikis, Sernova President and CEO. “We at Sernova see this collaboration as the beginning of a long-term relationship in supporting the clinical development progression of our therapeutic cell and device applications. With their clinical trial experience across six continents in bringing research sites, patients, and sponsors together, CTI will be an invaluable member of Sernova’s development team.”

In further developments, Sernova also announced that it has retained Mackie Research Capital Corporation ("Mackie") to provide market making services to the company in compliance with the guidelines of the TSX Venture Exchange (the "TSXV"). Mackie will trade shares of Sernova on the TSXV for the purposes of maintaining an orderly market and improving the liquidity of Sernova’s shares. In consideration for their services, Sernova has agreed to pay Mackie $3,000 per month for a period of 12 months which is extendable. The agreement may be terminated at any time by Sernova or Mackie. There are no performance factors contained in the agreement and Mackie will not receive any shares or options from Sernova as compensation for the services. Sernova and Mackie are unrelated and unaffiliated entities, but Mackie and/or its clients may have an interest, directly or indirectly, in the securities of Sernova. The agreement is subject to approval of the TSXV.

About Sernova

Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing its Cell Pouch System, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells). Sernova’s Cell Pouch System, following implantation, is thought to form a vascularized tissue environment for the housing and long-term survival and function of therapeutic cells. It is anticipated that these therapeutic cells may release necessary proteins or hormones missing from the body to treat chronic diseases as an alternative to daily administration of drugs. For more information visit www.sernova.com

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, and other disease populations. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com

About Mackie Research Capital Corporation Mackie is one of Canada's largest independent full service investment firms, and proudly traces its roots back to 1921. Mackie is privately owned by many of its 300 employees. As a fully integrated national investment dealer, Mackie offers a full complement of capital markets and wealth management services to private clients, institutions and growth companies. For more information visit www.mackieresearch.com

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Allison Schroeder: CTI Media Contact Tel: 513-598-9290 aschroeder@ctifacts.com

Forward-Looking Statements

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 30, 2016 30 September, 2016

Sernova Announces Appointment of New CFO


Pharma Veteran Scott Langille brings over 25 years of experience in both Canada and the United States to Sernova

Source: Sernova Corp September 30, 2016, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – September 30, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce today the appointment of Scott Langille as Chief Financial Officer.

“Sernova is pleased to have attracted a senior executive with extensive experience in corporate and operational finance, in all facets of life sciences including brand and generic pharmaceuticals, medical devices and biotechnology with a highly developed ability to attract and manage pharma partnerships, acquisitions and mergers,” remarked Dr. Philip Toleikis, Sernova’s President and CEO.

Mr. Langille’s most recent pharma successes includes CFO of Tribute Pharmaceuticals (TSXV:TRX or OTCQX :TBUFF), a diversified healthcare company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. Mr. Langille was responsible for strategic direction, business development initiatives, investor relations, corporate financing, financial operations and supply chain, and supported Tribute to a successful M&A event with Pozen to create Aralez Pharmaceuticals.

Prior to joining Tribute in September of 2007, Mr Langille was CFO of Virexx Medical Corp., a Canadian public biotech company, where he was responsible for strategic direction, business development initiatives, investor relations, corporate financing activities and financial operations. Prior to Virexx, he was Vice President at Biovail Pharmaceuticals and earlier held management positions at AltiMed Pharmaceuticals and Zimmer Canada.

Commenting on his appointment, Mr. Langille said, “I am excited to have the opportunity to join Sernova at this important juncture and look forward to working with the management team and Board to leverage my relevant experiences to create substantial value for our shareholders.”

We wish Ralph Deiterding, Sernova’s previous CFO, well in his future endeavors.

For further information contact:

Philip Toleikis, Ph.D., President and CEO. Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com

Ray Matthews & Associates. Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 12, 2016 12 July, 2016

Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes


$2.45 million USD awarded to advance Sernova’s Cell Pouch System(TM) (CPS) technologies in a US FDA Clinical Trial with Initiation Scheduled for the Second Half of 2016

Source: Sernova Corp July 12, 2016, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – July 12, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce today it has entered into a research funding agreement with JDRF, the leading global organization funding and advocating for type 1 diabetes (T1D) research. The purpose of the funding is to advance human clinical trials of Sernova’s CPS technologies for treatment of hypoglycemia unawareness patients with severe type 1 diabetes. T1D is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose.

JDRF will provide Sernova up to $2.45 million USD to support a clinical trial at a major transplantation center in the United States. The goal of the study is to provide patients with hypoglycemia unawareness a novel cell therapy treatment utilizing Sernova’s proprietary, highly vascularized, cell macroencapsulated implantable and scalable device to reduce or eliminate the need for injections of exogenous insulin. “JDRF has previously provided funding to advance the development of Sernova’s technologies through a preclinical collaboration with Massachusetts General Hospital, and we are proud to continue our support as Sernova’s technologies progress into new safety and efficacy clinical trials,” said Derek Rapp, JDRF President and CEO. “JDRF is excited about this collaboration, which advances research in encapsulated cell therapies, and will continue to drive progress toward our mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications.” “Sernova and JDRF are tightly aligned in our vision to see cell-based therapies developed to reduce disease burden and significantly increase the quality of life for people living with T1D,” remarked Dr. Philip Toleikis, Sernova’s President and CEO. “We see our work with JDRF on this important clinical trial as an exciting opportunity to more rapidly advance Sernova’s therapies to treat people with diabetes and address many of the shortcomings and challenges of current insulin therapy.” “Sernova’s progression to human clinical trials is an incredible accomplishment in the global diabetes research agenda,” said Dave Prowten, President and CEO of JDRF Canada. “I am particularly proud of this trial being a part of the JDRF portfolio because it supports advancements of the best and brightest research minds in Canada at Sernova. Also, this is a shining example of the international collaboration fostered by projects funded by JDRF. Working together with our global partners, we can accelerate this type of transformative research and ensure it becomes available for the T1D community.”

To date, there is no cure for T1D, and people living with the disease are dependent on insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

About Sernova Sernova Corp is a clinical stage regenerative medicine Company developing highly disruptive medical technologies to improve the treatment and quality of life of people with chronic debilitating metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device which forms highly vascularized chambers, ideal for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required to treat disease. For more information, please visit Sernova.com or follow us on Twitter: @SernovaCorp

About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 30, 2016 30 June, 2016

SERNOVA COMPLETES PRIVATE PLACEMENT OF $4,200,000


LONDON, ONTARIO –June 30, 2016 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it has completed a non-brokered private placement of $4.2 million, pursuant to which Sernova issued a total of 16,800,000 units in two closing (June 27, 2016 and June 30, 2016).

Each unit issued in the private placement consists of one common share and one common share purchase warrant, and each warrant is exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the 20-day volume weighted price of the shares exceeds $0.50.

The gross proceeds from the private placement will be used to fund a US-based clinical trial ($2.5 million is allocated) and to fund Sernova's research and development programs including corporate and academic collaborations ($1.2 million is allocated) utilizing its platform technology to treat diabetes and other serious disease conditions, as well as for general corporate purposes (approximately $0.5 million).

The Company compensated finders by way of cash fees of $130,462.50 and 521,850 non-transferable finder warrants, each such finder warrant having the same terms as the Unit warrants. Finders were Richardson GMP, Echelon Wealth Partners, Gravitas Securities Inc., Aventine Management Group, Raymond James, Mackie Research Capital Corporation, Canaccord Genuity, CMF AG and CRF Finance AG.

All of the securities issued in connection with the private placement are subject to a four month hold period from the date of issuance in accordance with applicable provincial securities laws in Canada. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements.

About Sernova

Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required for the treatment of disease.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Specifically, although the company intends to expend the proceeds from the private placement as described above, there may be circumstances where for sound business reasons, a reallocation of funds may be deemed prudent or necessary. While actual expenditures may differ from the above amounts and allocations, the net proceeds will be used by the company in furtherance of its business. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 29, 2016 29 June, 2016

Sernova Increases Private Placement to $4,200,000


Source: Sernova Corp June 29, 2016, 6:00 a.m. EDT

LONDON, ONTARIO –June 29, 2016 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the “Units”) at $0.25 per Unit, to accommodate additional over-subscriptions (see our news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement).

Sernova issued 8,000,000 Units for $2,000,000 in the first closing on June 27, 2016 and expects to close the balance of the private placement, being 8,800,000 Units for $2,200,000, in a second and final closing on June 30, 2016. Each Unit consists of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50.

Completion of the private placement is subject to the receipt of the approval of the TSX Venture Exchange. All securities issued in connection with the private placement will be subject to a statutory hold period of four months. The Company expects to compensate finders on a portion of the increased private placement consisting of 7% in cash and 7% in finder warrants, or a combination thereof.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements.

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System(TM) and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 27, 2016 27 June, 2016

Sernova Announces $2,000,000 First Closing of Private Placement


Due to Oversubscription, Offering Increased to $3,750,000

Source: Sernova Corp June 27, 2016, 6:00 a.m. EDT

LONDON, ONTARIO –June 27, 2016 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is closing today $2,000,000 of its non-brokered private placement announced on June 21, 2016. In addition, as the Company has received over-subscriptions of $1,650,000, it is increasing the total amount of the non-brokered private placement offering to $3,750,000 for a total offering of 15,000,000 units (the “Units”) at $0.25 per Unit. The Company plans to close the balance of the placement, Thursday, June 30th, 2016.

“We are pleased with the very strong interest from investors in Sernova’s future in the regenerative medicine space as indicated by the oversubscription of the private placement,” said Dr. Philip Toleikis, President and CEO of Sernova.

Net proceeds from the private placement will be used to fund Sernova's regenerative medicine clinical program and collaborations utilizing the Company’s platform technology to treat diabetes and other serious disease conditions, as well as for general corporate purposes.

In the first closing today, Sernova will issue 8,000,000 Units at $0.25 per Unit for gross proceeds of $2,000,000. Each Unit to be issued will consist of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50.

Also, in respect of the first closing, the Company expects to compensate finders by way of cash fees of $132,912.50 and 531,650 non-transferable finder warrants, each such finder warrant having the same terms as the Unit warrants. The Company may also compensate finders on a portion of the increased private placement consisting of 7% in cash and 7% in finder warrants, or a combination thereof.

Completion of the $3,750,000 private placement is subject to the receipt of the approval of the TSX Venture Exchange. All securities issued in connection with the private placement will be subject to a statutory hold period of four months. This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements.

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System(TM) and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 21, 2016 21 June, 2016

Sernova Announces Non-brokered Private Placement


Net proceeds to fund Sernova’s collaborations and a US-based clinical trial anticipated to commence in the second half of 2016

Source: Sernova Corp June 21, 2016, 6:00 a.m. EDT

LONDON, ONTARIO –June 21, 2016 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announced today that it has arranged a non-brokered private placement for gross proceeds of $2,000,000. The private placement consists of 8,000,000 units (the “Units”) at a price of $0.25 per Unit.

Each Unit will consist of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.35 per share for a 24 month exercise period, subject to abridgement of the exercise period. Abridgement may occur with 30 days’ notice to holders (after the expiry of the 4 month hold period) if the 20 day volume weighted price of SVA shares exceeds $0.50 per share.

Net proceeds from the private placement will be used to fund Sernova's collaborations utilizing our Cell Pouch System platform technologies to treat diabetes and other serious disease conditions, as well as to support a US-based Phase I/II diabetes clinical trial anticipated to commence in the second half of 2016, and for general corporate purposes.

All securities issued in connection with the private placement will be subject to a statutory hold period of four months. The Company will compensate finders on a portion of the private placement, such compensation consisting of 7% in cash or 7% in finder warrants, or a combination thereof.

Completion of the private placement is subject to the receipt of all necessary corporate and regulatory approvals, including approval of the TSX Venture Exchange.

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells), which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief that Sernova will be able to raise additional capital to fund its clinical programs. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 15, 2016 15 March, 2016

Sernova Announces First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update


Source: Sernova Corp

March 15, 2016, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – March 15, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today its financial results for the three months ending January 31, 2016 and provided an overview of recent Company highlights.

“Sernova has achieved significant milestones in the first fiscal quarter of 2016 both from the capital markets perspective and in expanding our highly disruptive regenerative medicine technology development programs for diabetes and hemophilia,” said Dr. Philip Toleikis, President and CEO. Selected Corporate Highlights through February 2016

• Sernova was selected as a member of the “2016 TSX Venture 50” and ranked fourth in the Life Sciences and Clean Technologies category based on a number of key measures of market performance, including market capitalization growth, share price appreciation and trading volume. The TSX ranked companies from among the 1,791 companies listed on the TSX Venture Exchange as of December 31, 2015.

• The European Commission’s Horizon 2020 program awarded a €5.6 million (approximately $8.5 million) non-dilutive grant to the HemAcure consortium, which consists of Sernova Corp and five European academic and private partners. The purpose is to advance the development of a GMP clinical grade factor VIII releasing therapeutic cell product in combination with Sernova’s Cell Pouch(TM) for the treatment of severe hemophilia A, a serious genetic bleeding disorder caused by missing or defective factor VIII in the blood stream. The therapeutic goal of the product is to use the patient’s own cells corrected for the factor VIII gene.

• The Company received an initial funding payment related to the HemAcure grant in the amount of €566,607 (approximately $873,000).

• Our clinical islet diabetes program was advanced by entering into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova’s licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive. This partnership accesses CCRM’s expertise in developing production processes for cellular therapies and is an important step in our plan to commercialize an unlimited supply of glucose responsive, insulin producing cells for the Cell Pouch System(TM) in order to address the broader population of patients with insulin dependent diabetes.

Highlights of financial results for the three months ended January 31, 2016

The Company ended the first quarter with approximately $3.6 million of cash and marketable securities at January 31, 2016, up from $2.9 million at October 31, 2015. For the three months ended January 31, 2016 and 2015, the Company reported a net loss for the period of approximately $0.7 million and $0.6 million, respectively, or a net loss per share of $0.00 for each period. The Company's financial information has been prepared in accordance with International Financial Reporting Standards (“IFRS”) and this selected information should be read in conjunction with Sernova's Financial Statements and Management's Discussion and Analysis for the three months ended January 31, 2016, as filed on SEDAR and also available from the Company’s website at: www.sernova.com.

On March 14, 2016, and in accordance with the Company’s 2015 Incentive Plan, Sernova granted 450,000 deferred share units to its directors and 3,080,000 incentive stock options to certain officers, employees and consultants of the Company, each such option being exercisable into a common share at a price of $0.225 per share on or before March 14, 2026.

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System(TM) and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 16, 2016 16 February, 2016

Sernova Receives First Payment from the European Commission’s Horizon 2020 Grant to Fund Development of a Cell-Based Hemophilia Therapeutic Using the Cell Pouch™


Payment represents the first non-dilutive installment to Sernova as consortium member from the €5.6Million ($8.5 million CAD) HemAcure Grant Award

Source: Sernova Corp

Tuesday, February 16, 2016, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – February 16, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, announced today it has received its initial € 566,500 ($875,000 CDN) installment of non-dilutive funds from the HemAcure Grant funded by the EU Horizon 2020 Program. Sernova will use the payment to fund activities related to the development of a GMP clinical grade Factor VIII releasing therapeutic cell product combined with Sernova’s Cell Pouch(TM) to treat severe hemophilia A, a serious genetic bleeding disorder caused by missing or defective factor VIII in the blood stream.

“We are excited that the HemAcure consortium partners, a group developing a therapeutic that is highly disruptive to the current standard of care treatments for hemophilia A, are already working diligently to advance the program. Together, we are working to address, with a sense of urgency, the critical challenges posed by severe hemophilia A,” remarked Dr. Philip Toleikis, Sernova President and CEO.

The therapeutic goal is to use the patient’s own cells after correcting for the factor VIII gene deficiency. These cells are placed in the implanted Cell Pouch(TM) and release factor VIII on a continual basis at a rate that is expected to significantly reduce disease-associated hemorrhaging and joint damage. The constant delivery of factor VIII from the corrected cells may also reduce or eliminate the need for multiple weekly infusions - the current standard of care for the prophylactic treatment of hemophilia A which uses plasma-derived or recombinant, genetically engineered factor VIII.

“Sernova continues to benefit from the judicious use of partnerships, grant applications and other forms of non-dilutive funding to advance our technology platform and products in development, thereby maximizing potential returns for our stakeholders,” added Dr. Toleikis.

Sernova has developed a highly innovative, scalable, implantable medical device (Cell Pouch(TM)) for the placement and long term survival and function of therapeutic cells. It has proven to be safe and efficacious in multiple small and large animal preclinical models and has demonstrated safety alone and with therapeutic cells in a clinical trial in humans for another therapeutic indication. We believe the Cell Pouch(TM) platform is the only such patented technology that when implanted under the skin is proven to become incorporated with blood vessel enriched tissue-forming chambers for the placement and long term survival and function of therapeutic cells.

About Hemophilia A

People with Hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency is the most common form of Hemophilia and is a genetic disorder caused by missing or defective FVIII, a blood clotting protein. Severe hemophilia occurs in about 60% of cases where the deficiency of FVIII is less than 1% of normal blood concentration. While it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous change in the gene. According to the US Centers for Disease Control and Prevention hemophilia occurs in about 1 in 5,000 births. If the prolonged bleeding occurs in the brain of a person with hemophilia, it can be fatal. Prolonged bleeding in joints can cause inflammatory responses and permanent joint damage. Approximately 20,000 people in the United States and 10,000 in Europe have the moderate or severe form of hemophilia A, as well as approximately 2,500 in Canada. All races and ethnic groups are equally affected by hemophilia A. Though there is no cure for the disease, it can be controlled with regular infusions of recombinant clotting FVIII. Annual costs for the treatment of the disease for each patient may range from $60,000 to $260,000 US for a total cost of between $2-5B per year in North America and Europe.

About Horizon 2020 Programme

Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over seven years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The project is funded as part of societal challenges “personalizing health and care” in a specific call about innovative treatments and technologies. New therapies, such as gene or cell therapies, often require technological innovation in the form of development of specific component tools and techniques such as isolation and multiplication of a cell or development of a scaffold, delivery of the therapy to the patient and for following-up the effect of the therapy in the patient. In particular, achieving therapeutic scale production and GMP standards at reasonable cost is often underestimated. The European Union aims to improve the development of advanced methods and devices for targeted and controlled delivery, and to bring these innovative treatments to the patient.

About HemAcure

HemAcure is the name of the consortium developing a product for hemophilia A. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 667421. The consortium members include the University Hospital Wurzburg (Coordinating Institute), IMS - Integrierte Management Systeme in Heppenheim, Germany, Universita del Piemonte Orientale “Amedeo Avogadro,” Loughborough University, GABO:mi Gesellschaft für Ablauforganisation: milliarium mbH & Co. and Sernova Corp. The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy within Sernova’s prevascularized Cell Pouch to treat this bleeding disorder that should ultimately lead to improved quality of life of the patients.

About Sernova

Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch™ and our expectations of the potential benefits of the consortium and the Horizon 2020 hemophilia project, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 05, 2016 5 February, 2016

Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies


Sernova resides in the top 3% of TSX Venture Exchange Companies in market performance

Source: Sernova Corp

February 5, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – February 5, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has received the ranking of fourth in the category of Life Sciences and Clean Technologies and has been selected as member of the “2016 TSX Venture 50” Companies. This is a prestigious group of top market performers from among the 1,791 companies listed on the Toronto Venture Exchange as of December 31, 2015. "We are honoured to be distinguished by the TSX from amongst all TSX Venture Companies and are appreciative of our investors who have rewarded our progress as acknowledged through the TSX Venture Exchange,” remarked Dr. Philip Toleikis, President and CEO. “We congratulate our peer companies in this category who have shown superior results in key metrics of market performance such as market capitalization growth, share price appreciation and trading volume – with Sernova providing a return of 118% in market cap appreciation in 2015. The shares of these companies also enjoyed a liquid market, with a total of 3.0 billion shares traded over the course of 2015,” added Dr. Toleikis.

“Sernova’s ongoing development of its platform technologies for cell therapy, the advancement of it programs in diabetes and hemophilia, and its focus on forging mutually beneficial pharmaceutical collaborations will, we believe, make 2016 another rewarding year for our shareholders and investors,” stated Frank Holler, Sernova Chairman. “This TSX Venture recognition adds to our growing profile in the public markets and we are most appreciative of receiving this distinction," added Mr. Holler.

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 26, 2016 26 January, 2016

Sernova Announces Agreement with CCRM to Produce Specialized Cells for the Treatment of Diabetes


CCRM to establish, optimize and validate methods for producing Sernova’s transformative cell-based therapies for Type-1 diabetes

Source: Sernova Corp

January 26, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – January 26, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova’s licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive.

“Sernova’s Cell Pouch System(TM) is a novel, preclinically validated and clinically tested platform for multiple types of therapeutic cells, including human islets,” said Dr. Philip Toleikis, President and CEO Sernova Corp. “Sernova’s CCRM partnership with CCRM’s expertise in developing production processes for cellular therapies is an important step in Sernova’s plan to commercialize an unlimited supply of glucose responsive, insulin producing cells for the Cell Pouch System. Sernova continues to seek out and evaluate optimal unlimited cell sources both internally developed and through corporate partnerships involving stem cell derived, and xenogeneic cell sources. Our manufacturing partnership with CCRM will provide the ability for the scale up production required to ensure successful commercialization of Sernova’s cellular therapies for diabetes,” added Dr. Philip Toleikis.

CCRM is a unique not-for-profit group that is solely focused on developing and commercializing cell therapy and regenerative medicine technologies. Sernova is a member of CCRM’s industry consortium, a group of nearly 50 companies formed to address bottlenecks in cell therapy and regenerative medicine product pipelines by enabling industry to engage with CCRM’s broad network of researchers and institutions. Industry consortium members represent key sectors in regenerative medicine – therapeutics, devices, reagents and cells as tools – and tremendous industry experience.

"As a member of CCRM’s industry consortium, Sernova is a valued partner in our quest to develop global breakthroughs in regenerative medicine,” remarked Michael May, President and CEO of CCRM. “Commercializing a regenerative medicine therapy for diabetes – the goal for Sernova and CCRM – has the potential to disrupt and transform current standard of treatment. We are excited about the timing of this partnership,” added Dr. May, “as it is our expectation that projects like this become candidates for the new advanced manufacturing initiative that we announced during a visit by Prime Minister Trudeau in mid-January.”

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System and our cell technologies, and manufacturing capabilities of CCRM are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 06, 2016 6 January, 2016

Sernova Corp to Present at the Biotech Showcase™ 2016 in San Francisco on January 13, 2016


Source: Sernova Corp January 6, 2016, 6:00 a.m. EDT

LONDON, Ontario, January 6, 2016– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be providing a corporate update at the 8th annual Biotech Showcase Conference in San Francisco, CA, at 4:00 p.m. PST on January 13, 2016 in San Francisco, California. In a full roster of business development meetings, Dr. Toleikis will also be updating key pharma and institutional audiences on the company's progress and future plans.

This conference occurs during the largest gathering of biopharmaceutical executives at parallel conferences in San Francisco which includes the J.P. Morgan Healthcare Conference which itself is the largest healthcare investment symposium in the industry, bringing together global industry leaders, emerging companies, technology innovators and members of the investment community. “Bio-Showcase is viewed as a preeminent gathering for leading life science professionals and brings about major global partnerships and advancements. It is considered an important and timely event for the company as investors, funds, institutions and pharma attend to explore collaborations with an eye to consolidate assets for global market opportunities,” remarked Dr. Toleikis.

About Biotech Showcase(TM)

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential partners in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives Now in its eighth year, Biotech Showcase is expected to attract upwards of 2,000 attendees. The meeting is being held January 11-13, 2016 in San Francisco, CA at the Parc 55, San Francisco, California.

About Sernova

Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.